Open Access

Significance of PD‑L1 clones and C‑MET expression in hepatocellular carcinoma

  • Authors:
    • Hyung‑Wook Chun
    • Ran Hong
  • View Affiliations

  • Published online on: April 5, 2019     https://doi.org/10.3892/ol.2019.10222
  • Pages: 5487-5498
  • Copyright: © Chun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Programmed cell death ligand 1 (PD‑L1) is an essential immune checkpoint protein implicated in immune evasion by malignant tumors. Overexpression of programmed cell death protein 1 (PD‑1) and its ligand PD‑L1 is associated with poor prognosis in various types of cancer. Recently, multiple advances have occurred in the area of cancer immunotherapy. Inhibiting the ligation of PD‑1 by PD‑L1 has been the major focus of anti‑tumor immunotherapy. In diagnostic pathology, it has become crucial to detect PD‑L1+ tumor cases using a validated immunohistochemistry (IHC) approach. Preliminary data demonstrate that C‑MET promotes survival of some (e.g., renal) cancer types through regulation of PD‑L1. However, C‑MET expression, and its association with PD‑L1, has not been well‑characterized in the context of hepatocellular carcinoma (HCC), and no anti‑HCC immunotherapy is currently available in Korea. Therefore, it is crucial to investigate the expression of C‑MET and PD‑L1, and their association with clinicopathologic factors, to facilitate the development of targeted treatments for HCC. PD‑L1 expression was examined in tumor cells (TC) and immune cells (IC) of 70 patient‑derived HCC specimens using IHC. Two anti‑PD‑L1 monoclonal antibodies (MAbs), SP263 and SP142, were utilized. Additionally, TC C‑MET expression was assessed. Correlations between PD‑L1 expression (as identified by both MAbs), C‑MET expression and clinicopathologic factors were assessed. More PD‑L1+ cases were identified via SP263 than via SP142 when assessing both TC and IC; in the former group, SP236 identified 14/70 positive cases, while SP142 identified only 2/70. In the latter group, SP236 identified 49/70 positive cases, while SP142 identified 30/70. Both MAbs demonstrated a higher frequency of PD‑L1 expression by IC than TC. The Edmondson‑Steiner grade statistically correlated with a higher frequency of SP236‑detected TC PD‑L1 expression. C‑MET was significantly associated with advanced tumor size and was positively correlated with SP263‑detected PD‑L1 expression in TC. These results suggest that C‑MET may serve a role in regulating PD‑L1 expression in HCC. Furthermore, while SP263 generally exhibited a higher sensitivity for PD‑L1 detection, concordance in PD‑L1+ case detection between the two different MAbs was generally good. These background data may be helpful in the development of targeted anti‑HCC immunotherapy focused on PD‑L1 or C‑MET, and in evaluating selection criteria for target populations best suited to such treatments.

References

1 

El-Serag HB: Hepatocellular carcinoma. N Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI

2 

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI

3 

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI

4 

Jung HI, Jeong D, Ji S, Ahn TS, Bae SH, Chin S, Chung JC, Kim HC, Lee MS and Baek MJ: Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with Hepatocellular carcinoma. Cancer Res Treat. 49:246–254. 2017. View Article : Google Scholar : PubMed/NCBI

5 

Vilarinho S and Taddei T: Therapeutic strategies for hepatocellular carcinoma: New advances and challenges. Curr Treat Options Gastroenterol. 13:219–234. 2015. View Article : Google Scholar : PubMed/NCBI

6 

Sangro B, Palmer D and Melero I: Immunotherapy of hepatocellular carcinoma. Hepat Oncol. 1:433–446. 2014. View Article : Google Scholar : PubMed/NCBI

7 

Chang H, Jung W, Kim A, Kim HK, Kim WB, Kim JH and Kim BH: Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma. APMIS. 125:690–698. 2017. View Article : Google Scholar : PubMed/NCBI

8 

Farkona S, Diamandis EP and Blasutig IM: Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 14:732016. View Article : Google Scholar : PubMed/NCBI

9 

Nishimura H, Agata Y, Kawasaki A, Sato M, Imamura S, Minato N, Yagita H, Nakano T and Honjo T: Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Int Immunol. 8:773–780. 1996. View Article : Google Scholar : PubMed/NCBI

10 

Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, et al: Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 66:3381–3385. 2006. View Article : Google Scholar : PubMed/NCBI

11 

Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG and Xu N: Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 108:19–24. 2006. View Article : Google Scholar : PubMed/NCBI

12 

Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, et al: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 104:3360–3365. 2007. View Article : Google Scholar : PubMed/NCBI

13 

Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY, Yang YP, Tien P and Wang FS: PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer. 128:887–896. 2011. View Article : Google Scholar : PubMed/NCBI

14 

Maine CJ, Aziz NH, Chatterjee J, Hayford C, Brewig N, Whilding L, George AJ and Ghaem-Maghami S: Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol Immunother. 63:215–224. 2014. View Article : Google Scholar : PubMed/NCBI

15 

Norde WJ, Hobo W, van der Voort R and Dolstra H: Coinhibitory molecules in hematologic malignancies: Targets for therapeutic intervention. Blood. 120:728–736. 2012. View Article : Google Scholar : PubMed/NCBI

16 

Zhang Y, Kang S, Shen J, He J, Jiang L, Wang W, Guo Z, Peng G, Chen G, He J and Liang W: Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) expression in epithelial-originated cancer: A meta-analysis. Medicine (Baltimore). 94:e5152015. View Article : Google Scholar : PubMed/NCBI

17 

Zhang L, Qiu M, Jin Y, Ji J, Li B, Wang X, Yan S, Xu R and Yang D: Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. Int J Clin Exp Pathol. 8:11084–11091. 2015.PubMed/NCBI

18 

Hsu MC, Hsiao JR, Chang KC, Wu YH, Su IJ, Jin YT and Chang Y: Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma. Mod Pathol. 23:1393–1403. 2010. View Article : Google Scholar : PubMed/NCBI

19 

Muenst S, Hoeller S, Dirnhofer S and Tzankov A: Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum Pathol. 40:1715–1722. 2009. View Article : Google Scholar : PubMed/NCBI

20 

Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC and Kwon ED: PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 13:1757–1761. 2007. View Article : Google Scholar : PubMed/NCBI

21 

Swaika A, Hammond WA and Joseph RW: Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol. 67:4–17. 2015. View Article : Google Scholar : PubMed/NCBI

22 

Miao L, Lu Y, Xu Y, Zhang G, Huang Z, Gong L and Fan Y: PD-L1 and c-MET expression and survival in patients with small cell lung cancer. Oncotarget. 8:53978–53988. 2017.PubMed/NCBI

23 

Gherardi E, Birchmeier W, Birchmeier C and Vande Woude G: Targeting MET in cancer: Rationale and progress. Nat Rev Cancer. 12:89–103. 2012. View Article : Google Scholar : PubMed/NCBI

24 

Goyal L, Muzumdar MD and Zhu AX: Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res. 19:2310–2318. 2013. View Article : Google Scholar : PubMed/NCBI

25 

Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, Zhou J, Li BZ, Shi YH, Xiao YS, et al: Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 15:971–979. 2009. View Article : Google Scholar : PubMed/NCBI

26 

Wang BJ, Bao JJ, Wang JZ, Wang Y, Jiang M, Xing MY, Zhang WG, Qi JY, Roggendorf M, Lu MJ and Yang DL: Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol. 17:3322–3329. 2011. View Article : Google Scholar : PubMed/NCBI

27 

Kleponis KJ, Skelton R and Zheng L: Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biol Med. 12:201–208. 2015.PubMed/NCBI

28 

El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, et al: Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 does escalation and expansion trial. Lancet. 389:2492–2502. 2017. View Article : Google Scholar : PubMed/NCBI

29 

Baik CS, Rubin EH, Forde PM, Mehnert JM, Collyar D, Butler MO, Dixon EL and Chow LQM: Immuno-oncology clinical trial design: limitations, challenges, and opportunities. Clin Cancer Res. 23:72017. View Article : Google Scholar

30 

Gelsomino F, Rossi G and Tiseo M: MET and small-cell lung cancer. Cancers (Basel). 6:2100–2115. 2014. View Article : Google Scholar : PubMed/NCBI

31 

Kim R, Keam B, Kwon D, Ock Cy, Kim M, Kim TM, Kim HJ, Jeon YK, Park IK, Kang CH, et al: Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma. World J Gastroenterol. 22:8389–8397. 2016. View Article : Google Scholar : PubMed/NCBI

32 

Zeng Z, Shi F, Zhou L, Zhang MN, Chen Y, Chang XJ, Lu YY, Bai WL, Qu JH, Wang CP, et al: Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PLoS One. 6:e236212011. View Article : Google Scholar : PubMed/NCBI

33 

Vennapusa B, Baker B, Kowanetz M, Boone J, Menzl I, Bruey JM, Fine G, Mariathasan S, McCaffery I, Mocci S, et al: Development of a PD-L1 companion diagnostic Immunohistochemistry assay (SP142) for atezolizumab. Appl immunohistochem Mol Morphol. 27:92–100. 2019. View Article : Google Scholar : PubMed/NCBI

34 

Schats KA, Van Vre EA, De Schepper S, Boeckx C, Schrijvers DM, Waelput W, Fransen E, Vanden Bempt I, Neyns B, De Meester I and Kockx MM: Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system. Histopathology. 70:253–263. 2017. View Article : Google Scholar : PubMed/NCBI

35 

Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, et al: Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial. Lancet. 389:67–76. 2017. View Article : Google Scholar : PubMed/NCBI

36 

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, et al: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet. 389:255–265. 2017. View Article : Google Scholar : PubMed/NCBI

37 

Sidaway P: Bladder cancer: Atezolizumab: An alternative to cisplatin? Nat Rev Urol. 14:672017. View Article : Google Scholar

38 

Mizugaki H, Yamamoto N, Murakami H, Kenmotsu H, Fujiwara Y, Ishida Y, Kawakami T and Takahashi T: Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. Invest New Drugs. 34:596–603. 2016. View Article : Google Scholar

39 

Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, et al: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet. 387:1909–1920. 2016. View Article : Google Scholar : PubMed/NCBI

40 

Rebelatto MC, Midha A, Mistry A, Sabalos C, Schechter N, Li X, Jin X, Steele KE, Robbins PB, Blake-Haskins JA and Walker J: Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagn Pathol. 11:952016. View Article : Google Scholar : PubMed/NCBI

41 

Diggs LP and Hsueh EC: Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. Biomark Res. 5:122017. View Article : Google Scholar : PubMed/NCBI

42 

Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, Fazzalari L, Zahaf K, Lalvée S, Washetine K, et al: Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: A potential issue for anti-PDL1 therapeutic strategies. Ann Oncol. 27:147–153. 2016. View Article : Google Scholar : PubMed/NCBI

43 

Kitazono S, Fujiwara Y, Tsuta K, Utsumi H, Kanda S, Horinouchi H, Nokihara H, Yamamoto N, Sasada S, Watanabe S, et al: Reliability of small biopsy samples compared with resected specimens for the determination of programmed death-ligand 1 expression in non-smallcell lung cancer. Clin Lung Cancer. 16:385–390. 2015. View Article : Google Scholar : PubMed/NCBI

44 

Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H and Nishimura M: B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 10:5094–5100. 2004. View Article : Google Scholar : PubMed/NCBI

45 

Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, et al: Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol. 25:1935–1940. 2014. View Article : Google Scholar : PubMed/NCBI

46 

Tang Y, Fang W, Zhang Y, Hong S, Kang S, Yan Y, Chen N, Zhan J, He X, Qin T, et al: The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget. 6:14209–14219. 2015. View Article : Google Scholar : PubMed/NCBI

47 

Gabrielson A, Wu Y, Wang H, Jiang J, Kallakury B, Gatalica Z, Reddy S, Kleiner D, Fishbein T, Johnson L, et al: Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC. Cancer Immunol Res. 4:419–430. 2016. View Article : Google Scholar : PubMed/NCBI

48 

Kim JH, Kim HS, Kim BJ, Jang HJ and Lee J: Prognostic value of c-Met overexpression in hepatocellular carcinoma: A meta-analysis and review. Oncotarget. 8:90351–90357. 2017.PubMed/NCBI

49 

Kondo S, Ojima H, Tsuda H, Hashimoto J, Morizane C, Ikeda M, Ueno H, Tamura K, Shimada K, Kanai Y and Okusaka T: Clinical impact of c-MET expression and its gene amplification in hepatocellular carcinoma. Int J Clin Oncol. 18:207–213. 2013. View Article : Google Scholar : PubMed/NCBI

50 

Takeuchi H, Bilchik A, Saha S, Turner R, Wiese D, Tanaka M, Kuo C, Wang HJ and Hoon DS: c-MET expression level in primary colon cancer: A predictor of tumor invasion and lymph node metastases. Clin Cancer Res. 9:1480–1488. 2003.PubMed/NCBI

51 

Ueki T, Fujimoto J, Suzuki T, Yamamoto H and Okamoto E: Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology. 25:862–866. 1997. View Article : Google Scholar : PubMed/NCBI

52 

Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, et al: c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 67:1670–1679. 2007. View Article : Google Scholar : PubMed/NCBI

53 

Shattuck DL, Miller JK, Carraway KL III and Sweeney C: Met receptor contributes to trastuzumab resistance of Her2overexpressing breast cancer cells. Cancer Res. 68:1471–1477. 2008. View Article : Google Scholar : PubMed/NCBI

54 

Arriola E, Cañadas I, Arumí-Uría M, Dómine M, Lopez-Vilariño JA, Arpí O, Salido M, Menéndez S, Grande E, Hirsch FR, et al: MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines. Br J Cancer. 105:814–823. 2011. View Article : Google Scholar : PubMed/NCBI

55 

Park S, Choi YL, Sung CO, An J, Seo J, Ahn MJ, Ahn JS, Park K, Shin YK, Erkin OC, et al: High MET copy number and MET overexpression: Poor outcome in non-small cell lung cancer patients. Histol Histopathol. 27:197–207. 2012.PubMed/NCBI

56 

Nakamura Y, Niki T, Goto A, Morikawa T, Miyazawa K, Nakajima J and Fukayama M: c-Met activation in lung adenocarcinoma tissues: An immunohistochemical analysis. Cancer Sci. 98:1006–1013. 2007. View Article : Google Scholar : PubMed/NCBI

57 

Ichimura E, Maeshima A, Nakajima T and Nakamura T: Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res. 87:1063–1069. 1996. View Article : Google Scholar : PubMed/NCBI

58 

Takanami I, Tanaka F, Hashizume T, Kikuchi K, Yamamoto Y, Yamamoto T and Kodaira S: Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: An evaluation of their expression as prognostic markers. Oncology. 53:392–397. 1996. View Article : Google Scholar : PubMed/NCBI

59 

Siegfried JM, Weissfeld LA, Singh-Kaw P, Weyant RJ, Testa JR and Landreneau RJ: Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res. 57:433–439. 1997.PubMed/NCBI

60 

Danilkovitch-Miagkova A and Zbar B: Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest. 109:863–867. 2002. View Article : Google Scholar : PubMed/NCBI

61 

Boccaccio C and Comoglio PM: Invasive growth: A MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer. 6:637–645. 2006. View Article : Google Scholar : PubMed/NCBI

62 

Wu F, Wu L, Zheng S, Ding W, Teng L, Wang Z, Ma Z and Zhao W: The clinical value of hepatocyte growth factor and its receptor-c-met for liver cancer patients with hepatectomy. Dig Liver Dis. 38:490–497. 2006. View Article : Google Scholar : PubMed/NCBI

63 

Wang ZL, Liang P, Dong BW, Yu XL and Yu DJ: Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: A retrospective study. J Gastrointest Surg. 12:327–337. 2008. View Article : Google Scholar : PubMed/NCBI

64 

Kelley PK, Verslype C, Cohn AL, Yang TS, Su WC, Burris H, Braiteh F, Vogelzang N, Spira A, Foster P, et al: Carbozantinib in hepatocellular carcinoma: Results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol. 28:528–534. 2017. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Chun, H., & Chun, H. (2019). Significance of PD‑L1 clones and C‑MET expression in hepatocellular carcinoma. Oncology Letters, 17, 5487-5498. https://doi.org/10.3892/ol.2019.10222
MLA
Chun, H., Hong, R."Significance of PD‑L1 clones and C‑MET expression in hepatocellular carcinoma". Oncology Letters 17.6 (2019): 5487-5498.
Chicago
Chun, H., Hong, R."Significance of PD‑L1 clones and C‑MET expression in hepatocellular carcinoma". Oncology Letters 17, no. 6 (2019): 5487-5498. https://doi.org/10.3892/ol.2019.10222